Clinical Trials Sponsored by Mereo BioPharma

Total 1398 results

United BioPharma

Not yet recruiting

UB-421 Combine With Optimized Background Therapy Regimen in Multi-Drug Resistant HIV-1 Infection Patients

HIV-1 Infection
SPARK Biopharma

Completed

SB17170 Phase1 Trial in Healthy Volunteer

Pharmacokinetics | Pharmacodynamics | Safety Issues | Tolerability

Korea, Republic of
CTI BioPharma

Terminated

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

COVID-19 | COVID | COVID19

United States
NImmune Biopharma

Completed

Efficacy and Safety of Oral BT-11 in Ulcerative Colitis

Ulcerative Colitis

United States, Bosnia and Herzegovina, Croatia, Poland, Ukraine
NImmune Biopharma

Withdrawn

Safety and Pharmacokinetics of Orodispersible BT-11 in Active Eosinophilic Esophagitis

Eosinophilic Esophagitis
NImmune Biopharma

Completed

Safety, Tolerability, and Pharmacokinetics of Oral BT-11 in Healthy Adult Male and Female Volunteers

Normal Healthy Volunteers

United States
Theravance Biopharma

Terminated

Efficacy and Safety of TD-1473 in Crohn's Disease (DIONE)

Crohn's Disease

United States, Bulgaria, France, Georgia, Germany, Greece, Hungary, Israel, Korea, Republic of, Poland, Portugal, Romania, Serbia, South Africa, Spain, Ukraine, Australia, Austria, Croatia, New Zealand, Russian Federation, United...
United BioPharma

Completed

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

HIV-1 Infection

Taiwan
Theravance Biopharma

Completed

TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)

Parkinson Disease | Orthostatic Hypotension | Neurogenic Orthostatic Hypotension | Hypotension, Orthostatic | Pure Autonomic Failure | Multiple System Atrophy (MSA) With Orthostatic Hypotension | Pure Autonomic Failure With Orthostatic Hypotension | Parkinson Disease With Orthostatic Hypotension

United States
Theravance Biopharma

Completed

A Study of TD-9855 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

ADHD | Attention-Deficit/Hyperactivity Disorder

United States
Theravance Biopharma

Completed

Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19

COVID-19

United States
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia (PAC326)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada, France, United Kingdom, Australia, Belgium, Germany, New Zealand, Netherlands, Russian Federation, Hungary, Czechia
Theravance Biopharma

Completed

First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19

Acute Lung Injury (ALI) Associated With COVID-19 | Inflammatory Lung Conditions Associated With COVID-19

United Kingdom
Theravance Biopharma

Completed

Single Dose Bioavailability and Ethnobridging PK Study in Healthy Subjects

Bowel Diseases, Inflammatory | Intestinal Disorder

United States
Theravance Biopharma

Completed

A Fixed-Sequence, Two-Period, Open-Label Drug-Drug Interaction Study to Assess the Effect of an Inhibitor of Cytochrome P450 Isoenzyme 3A4 and Permeability Glycoprotein 1 on the Pharmacokinetics of TD-1211

Healthy

United States
Theravance Biopharma

Completed

Multiple Ascending Dose Study of TD-0714 in Healthy and Elderly Subjects

Healthy Adults, Elderly Subjects

United States
Theravance Biopharma

Completed

TD-6450 MAD Study in HCV Infected Subjects

Hepatitis C | HCV

United States
Theravance Biopharma

Completed

TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects

Bowel Diseases, Inflammatory | Intestinal Disorders

United States
Theravance Biopharma

Completed

Multiple Dose Ethnobridging PK Study in Healthy Subjects

Inflammatory Bowel Diseases | IBD

United States
Theravance Biopharma

Completed

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

Constipation

United States
CTI BioPharma

Terminated

CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy

Prostate Cancer

United States
CTI BioPharma

Withdrawn

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

NSCLC

United States
CTI BioPharma

Withdrawn

Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL

Non-Hodgkin's Lymphoma

United States
CTI BioPharma

Terminated

Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Lung Cancer

United States
United BioPharma

Withdrawn

the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients

HIV-1 Infection
NuSirt Biopharma

Completed

The Effect Of NS-0200 Versus Placebo On Hepatic Fat Content In Patients With Non Alcoholic Fatty Liver Disease

NAFLD

United States
NuSirt Biopharma

Completed

Dose Comparisons of Leucine-Metformin Combinations on Blood Glucose Levels In Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

United States
NuSirt Biopharma

Completed

An Extension Protocol to Evaluate Dose Comparisons of Leucine-Metformin Combinations in Type 2 Diabetic Patients

Type 2 Diabetes Mellitus

United States
Array BioPharma

Completed

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

AML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDS

United States, Australia, Italy, Spain, France, Switzerland, United Kingdom
Recepta Biopharma

Terminated

Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

Brazil
Array BioPharma

Terminated

LGX818 in Combination With Agents (MEK162; BKM120; LEE011; BGJ398; INC280) in Advanced BRAF Melanoma (LOGIC)

Melanoma

Canada, Spain, Australia, Switzerland, Germany, United States
Array BioPharma

Terminated

Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.

Locally Advanced Metastatic BRAF Mutant Melanoma

Australia, Canada, Netherlands, United States
Pronova BioPharma

Terminated

Efficacy and Safety of PRC-4016 in Subjects With Mixed Dyslipidemia

Dyslipidemia

United States
Pronova BioPharma

Completed

PRC-4016 (Icosabutate) Phase I Drug-drug Interaction Study

Healthy

United Kingdom
CTI BioPharma

Terminated

Comparative Trial for Pixantrone in Combination With Rituximab in Indolent Non-Hodgkin's Lymphoma

Lymphoma, Follicular | Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade

United States
Theravance Biopharma

Completed

Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

Alzheimer's Disease

United States
Array BioPharma

Completed

A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer

Pancreatic Cancer | Advanced Cancer

United States
Limerick BioPharma

Withdrawn

Investigation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LIM-0705 in Male Subjects With Impaired Glucose Tolerance (LIM)

Impaired Glucose Tolerance
CTI BioPharma

Completed

Phase II CT-2103/Carboplatin in Ovarian Cancer

Ovarian Neoplasm

United States
Lantu Biopharma

Not yet recruiting

An Open Label Study of Gene Therapy Product in Spinal Muscular Atrophy Patients

Spinal Muscular Atrophy
Huons Biopharma

Recruiting

To Evaluate the Efficacy and Safety of LIZTOX in Subjects With Benign Masseteric Hypertrophy

Benign Masseteric Hypertrophy

Korea, Republic of
Cue Biopharma

Recruiting

A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer

United States
Vor Biopharma

Recruiting

A Long-term Follow-up Study of Patients Who Received VOR33

Leukemia, Myeloid, Acute

United States, Canada
United BioPharma

Recruiting

A Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Efficacy of UB-221 IV Infusion as an add-on Therapy in Patients With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria

Taiwan
Vor Biopharma

Recruiting

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Canada
UWELL Biopharma

Not yet recruiting

Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma

Recurrent Glioblastoma
POINT Biopharma

Active, not recruiting

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Soft Tissue Sarcoma | Colorectal Cancer | Esophageal Cancer | Cholangiocarcinoma | Head and Neck Squamous Cell Carcinoma | Pancreatic Ductal Adenocarcinoma | Melanoma (Skin)

United States, Canada
CTI BioPharma

Withdrawn

Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment (Hepatic)

Metastatic Cancer

United States
United BioPharma

Withdrawn

To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults

HIV-1 Infection

China
Theravance Biopharma

Terminated

Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure (REDWOOD)

Parkinson's Disease (PD) | MSA | Symptomatic Neurogenic Orthostatic Hypotension | Pure Autonomic Failure (PAF)

United States, Spain, United Kingdom, Canada, France, Estonia, Australia, Israel, Denmark, Italy, Poland, New Zealand, Germany, Ukraine, Austria, Bulgaria, Portugal, Hungary, Russian Federation

Clinical Trials Sponsored by Mereo BioPharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations